A pharmaceutical formulation for the treatment of HIV is provided. Theformulation is a combination of a nucleosidereverse transcriptase inhibitor and a nucleotide reverse transcriptaseinhibitor in which the combination has an increased stabilityover prior, art combination therapies. The invention also provides apharmaceutical product containing the formulation.